Efficacy of Homoeopathic medicine Rhus tox. 30 on lymphatic filariasis.

To evaluate the effectiveness of Rhus tox. 30 vis-a-vis individualised homoeopathic medicines in preventing the attacks of acute adenolymphangitis and grade I, grade II lymphoedema due to lymphatic filariasis: -A randomised double-blind placebo controlled clinical trial. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/066895

Enrollment

135

Registered

2024-05-07

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B74- Filariasis

Interventions

Intervention1: Rhus tox 30: Specific homoeopathic medicine Rhus tox 30 will be given to the patients with grade 1 & grade 2 lymphoedema due to LF as per randomization chart.4 nos. of gls of size 30 mo

Eligibility

Inclusion criteria

Inclusion criteria: -Patients of both male and female aged above 18 years with grade I and grade II lymphoedema due to LF or with ADL complaints. -Patients with controlled DM and Hypertension. -Written informed consent from the patients.

Exclusion criteria

Exclusion criteria: -Grade III and IV lymphoedema cases due to LF -Patients having lymphoedema due to non-filarial causes. -Patients having uncontrolled/ non-treated systemic disorders like diabetes, hypertension, cardiovascular disorders etc.

Design outcomes

Primary

Measure	Time frame
Frequency, intensity and duration of subsequent ADL attacks as measured by ADL score during six months of follow up period compared to six months history at baseline. Changes in size of lymphoedema after six months treatment compared to baseline will be done by measuring of limb circumference by using guidelines of the Australasian Lymphology Association. Timepoint: At the end of 6 months treatment.	—

Measure

Time frame

Frequency, intensity and duration of subsequent ADL attacks as measured by ADL score during six months of follow up period compared to six months history at baseline. Changes in size of lymphoedema after six months treatment compared to baseline will be done by measuring of limb circumference by using guidelines of the Australasian Lymphology Association. Timepoint: At the end of 6 months treatment.

—

Secondary

Measure	Time frame
To assess the effects of Rhus tox-30 & individualised homeopathic medicines on inflammatory cytokines, acute phase protein like CRP, IL-1ß, IL-6, IL-12 & TNF-a will be measured at baseline & 7th day of ADL attack. Quality of Life will be assessed by Lymphatic Filariasis Specific Quality of Life Questionnaire (LFSQQ) at end of six months follow up compared to baseline. Timepoint: At 7th day of ADL attack. At end of 6 months treatment.	—

Measure

Time frame

To assess the effects of Rhus tox-30 & individualised homeopathic medicines on inflammatory cytokines, acute phase protein like CRP, IL-1ß, IL-6, IL-12 & TNF-a will be measured at baseline & 7th day of ADL attack. Quality of Life will be assessed by Lymphatic Filariasis Specific Quality of Life Questionnaire (LFSQQ) at end of six months follow up compared to baseline. Timepoint: At 7th day of ADL attack. At end of 6 months treatment.

—

Countries

India

Contacts

Public ContactDr Akhyaya Kumar Prusty

Regional Research Institute for Homoeopathy

prustyakshayakumar@gmail.com9778461673

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026